159 related articles for article (PubMed ID: 12038454)
1. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
Salven P; Orpana A; Teerenhovi L; Joensuu H
Blood; 2000 Dec; 96(12):3712-8. PubMed ID: 11090051
[TBL] [Abstract][Full Text] [Related]
3. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
5. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1997 Oct; 90(8):3167-72. PubMed ID: 9376599
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
7. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.
el-Far M; Fouda M; Yahya R; el-Baz H
J Physiol Biochem; 2004 Dec; 60(4):253-8. PubMed ID: 15957243
[TBL] [Abstract][Full Text] [Related]
8. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
10. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
11. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
12. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Ugurel S; Rappl G; Tilgen W; Reinhold U
J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma.
Gunsilius E; Petzer AL; Gastl G
Br J Haematol; 2000 Mar; 108(3):661-3. PubMed ID: 10847704
[No Abstract] [Full Text] [Related]
14. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
[TBL] [Abstract][Full Text] [Related]
15. [Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients].
Wróbel T; Mazur G; Usnarska-Zubkiewicz L; Kuliczkowski K
Pol Arch Med Wewn; 2004 Aug; 112(2):919-23. PubMed ID: 15675266
[TBL] [Abstract][Full Text] [Related]
16. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
17. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
18. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.
Huang SP; Wu MS; Wang HP; Yang CS; Kuo ML; Lin JT
J Gastroenterol Hepatol; 2002 Nov; 17(11):1165-9. PubMed ID: 12453275
[TBL] [Abstract][Full Text] [Related]
19. VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.
Yang J; Li W; He X; Zhang G; Yue L; Chai Y
Dis Markers; 2015; 2015():786790. PubMed ID: 25810565
[TBL] [Abstract][Full Text] [Related]
20. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.
Karayiannakis AJ; Syrigos KN; Polychronidis A; Zbar A; Kouraklis G; Simopoulos C; Karatzas G
Ann Surg; 2002 Jul; 236(1):37-42. PubMed ID: 12131083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
